Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Health EN ↓ 223 episodes

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology . Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The E...

Be sure to visit the podcast's website and support the creator: www.hcplive.com

Author

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Category

Health

Podcast website

www.hcplive.com

Latest episode

Nov 16, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026 16.11.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives ! Late-breaking data from the American Heart Association (AHA) Scientific Sessions 2026 are reopening debate on blood pressure targets in diabetes, the cardiovascular profile of dual incretin-glucagon agonists, and oral therapy for obstructive sleep apnea (OSA). On a recent episode of Diabetes Dialogue, coho...

Tubeless Mobi Clearance, CGM Choice, and Eversense Freedom 16.11.2026

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, round up several recent developments across insulin pumps and continuous glucose monitoring. They discuss a new regulatory decision expanding wearable options for automated insulin delivery, including what it could mean for patient choice, site management, and day-to-day use. The hosts then turn to upcom...

Retatrutide Tops Semaglutide on A1C, Weight in T2D 12.11.2026

Triple agonism is reshaping expectations for weight loss in type 2 diabetes , a population historically less responsive to incretin-based therapy. New head-to-head phase 3 data show retatrutide more than doubled the weight reduction achieved with the highest approved dose of semaglutide (Ozempic). On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, revie...

CONNECT Trial Backs CGM in Non-Insulin Type 2 Diabetes 12.11.2026

Continuous glucose monitoring (CGM) is standard of care in insulin-treated diabetes, but evidence for its use in type 2 diabetes managed without insulin has lagged. New randomized data from the CONNECT trial suggest real-time CGM may substantially improve glycemic control in this much larger population. On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP,...

Building A Consensus Definition for Fully Closed-Loop Systems 27.10.2026

On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, talk with Brynn Marks, MD, MSHPEd, of Breakthrough T1D about where automated insulin delivery is headed. They discuss how next-generation systems might be evaluated and what the shift could mean for people with diabetes and the clinicians who support them. Full episode: https://www.hcplive.com/view/diabetes-dialo...

MiniMed Vivera Data and Twiist Type 2 Clearance 23.10.2026

Automated insulin delivery keeps moving toward systems that ask less of the people using them. In this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, look at two recent developments and talk through what they mean for clinical practice. In this episode: First-in-human results for the MiniMed Vivera algorithm, and how it performed when participants skipped meal announ...

Twiist AID Data and the New ADA/EASD Type 2 Algorithm 16.10.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives ! Automated insulin delivery (AID) is becoming the standard approach for insulin-requiring type 2 diabetes (T2D), and new pivotal data suggest a fourth system may soon join the 3 already cleared for this population. On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DN...

Screening, Cell Therapy, and Adjunctive Agents at Breakthrough-T1D 15.10.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives ! Population-level screening for type 1 diabetes (T1D) is moving into clinical practice, raising questions about who to screen, how to stage results, and how to deliver disease-modifying therapy at scale. On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recapped...

Weekly Insulin Efsitora Alfa Gets FDA Approval for Type 2 Diabetes 24.09.2026

On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP-BC, talk through the latest addition to the weekly basal insulin landscape and what it means for clinicians starting or switching patients. Their conversation centers on real-world considerations for bringing a new insulin option into practice. Watch the video and get the full description: https://www.hcplive...

Finerenone Approved for CKD in Type 1 Diabetes 18.09.2026

Chronic kidney disease remains a persistent risk for people with type 1 diabetes, with roughly 30% of this population in the US developing the complication despite optimized glucose, blood pressure, and lipid management. Until now, no therapy directly targeted the mineralocorticoid receptor pathway implicated in this progression for this group. On a recent episode of Diabetes Dialogue: Technology,...

Beta Bionics Mint Patch Pump Gains FDA Clearance 15.09.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives ! Tubeless insulin delivery is entering a new phase of competition, as Beta Bionics announced FDA clearance of Mint, its first patch pump, alongside a forthcoming algorithm update designed to individualize glycemic targets without carb counting.1,2 On a recent episode of Diabetes Dialogue, hosts Diana Isaacs...

Tirzepatide's New CV Indication and the STAREE Statin Trial 10.09.2026

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take on 2 recent developments that are reshaping how clinicians think about cardiovascular risk in people with diabetes. They start with a newly expanded indication for a dual incretin therapy, discussing what the supporting evidence means in practice and which patients may now be eligible. The hosts the...

Non-Invasive EEG Sensor Aims to Track Glucose in Real Time 26.08.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! Non-invasive glucose monitoring is entering a new phase, with an EEG-based wearable positioned to sense blood sugar through brain rhythms rather than interstitial fluid. Early data from the developer suggest the approach may anticipate glucose changes ahead of standard continuous glucose monitors (CGMs), a...

FreeStyle Libre Duo Cleared for Ketone Monitoring 26.08.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! Diabetic ketoacidosis remains a leading cause of preventable hospitalization in diabetes care, yet ketone testing has lagged far behind glucose monitoring in both accuracy and adoption. Continuous ketone monitoring aims to close this gap, giving clinicians and patients a real-time window into a metabolic st...

Ultra-rapid insulin, IcoSema advance in type 2 diabetes 24.08.2026

Insulin-resistant patients with type 2 diabetes who require high-dose therapy have long lacked a rapid-acting option concentrated enough for compact insulin pumps. New pharmacokinetic data on an ultra-rapid U-500 insulin aspart, alongside additional phase 3 results for a combined once-weekly insulin icodec-semaglutide regimen, both aim to close persistent gaps in insulin delivery for this populati...

Weekly Insulin Icodec Now Available for Type 2 Diabetes 11.08.2026

Once-weekly basal insulin therapy has moved from clinical trial data to pharmacy shelves, offering clinicians a new option for patients who struggle with the daily burden of insulin injections. The shift addresses a persistent adherence problem in basal insulin therapy, where missed or inconsistent daily dosing undermines glycemic control. In this episode of Diabetes Dialogue, hosts Diana Isaacs,...

Tech, Screening, and Care Highlights from ADCES 2026 10.08.2026

Advances in diabetes care rarely arrive through a single channel, and the 2026 annual meeting of the Association of Diabetes Care and Education Specialists (ADCES) reflected this breadth, with new insulin delivery hardware, cardiometabolic risk management, and endocrine screening criteria all drawing attention from clinicians in Columbus, Ohio. On a recent episode of Diabetes Dialogue, recorded on...

Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss 04.08.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! Triple hormone receptor agonism is emerging as a frontier in metabolic disease treatment, and topline phase 3 results for retatrutide suggest the strategy can push weight loss and glycemic control beyond current incretin therapies, even as a separate JAMA analysis raises questions about oversight in online...

Evolving Wearable Insulin Delivery Devices - AID, CGM, and More 30.06.2026

To begin the episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the rapidly evolving landscape of wearable insulin delivery, focusing on recent developments in patch pump technology and the growing number of tubeless insulin delivery systems entering the market. The conversation centers on the recent FDA clearance of the Pivot patch pump from Modular Medical, which the hosts...

Tegoprubart and Freedom from Insulin in Type 1 Diabetes 29.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! To begin the episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss recent advances in type 1 diabetes (T1D) research following presentations at the American Diabetes Association (ADA) Scientific Sessions and the American Association of Clinical Endocrinology (AACE) Annual Meeting. They focu...

Signos and the Science of Weight Loss 23.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new real-world data evaluating the Signos platform, an FDA-cleared digital weight-loss solution that combines the Dexcom Stelo continuous glucose monitor (CGM) with artificial intelligence–driven behavioral coaching. The platfo...

Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients 18.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a series of major pediatric diabetes advancements announced around the American Diabetes Association (ADA) Scientific Sessions 2026, highlighting how recent regulatory decisions are expanding treatment options and improving acc...

CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 11.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest major trial results like CONNECT, TRIUMPH, and TRANSCEND. To begin the episode, Isaacs and Bellini, discuss maj...

The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB 10.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this special episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in Ner Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Amit Gupta, MBBS, DNB, diabetologist, executive director of the Global Metabolic Health Alliance, and chair...

Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS 08.06.2026

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the...

Listen to the Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.